Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.73 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2709643 | 1.00 | DPP4 (0.73) | DPP4DPP8DPP9 | |
| Bromide SCHEMBL2709645 | 0.94 | DPP4 (0.77) | DPP4DPP8DPP9 | |
| Bromide SCHEMBL2707472 | 0.89 | DPP4 (0.77) | DPP4DPP8DPP9 | |
| Bromide SCHEMBL2712036 | 0.88 | DPP4 (0.86) | DPP4 | |
| Bromide SCHEMBL2707473 | 0.84 | DPP4 (0.80) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL2710136 | 0.84 | DPP4 (0.98) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL2708104 | 0.84 | DPP4 (0.86) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL2711570 | 0.83 | DPP4 (0.72) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL2708597 | 0.83 | DPP4 (0.69) | DPP4DPP8DPP9 | |
| Bromide SCHEMBL2712041 | 0.83 | DPP4 (0.98) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.